摘要
目的:评价硝苯地平治疗孕妇早产的疗效与安全性。方法:计算机检索相关数据库,收集硝苯地平治疗早产的随机和半随机试验,对符合纳入标准的临床研究进行Meta分析。结果:共纳入18篇文献。在妊娠延长48h,72h,7d以上的人数、新生儿体质量及降低新生儿疾病方面,硝苯地平组优于基础治疗组,但孕妇不良反应发生率较高。与硫酸镁组相比,硝苯地平组显效时间、妊娠延长48h的孕妇数、孕妇不良反应发生率RR(95%CI)分别为-0.48(-0.88,-0.08),1.12(1.01,1.25),0.58(0.46,0.73)。与β2肾上腺受体激动剂相比,硝苯地平组孕妇不良反应发生率RR(95%CI)为0.37(0.27,0.50)。与阿托西班相比,硝苯地平组显效快,但孕妇不良反应发生率增加。结论:与基础治疗相比,硝苯地平提高保胎成功率、增加新生儿体质量、降低新生儿发病率,但孕妇不良事件发生率较高;硝苯地平显效时间优于硫酸镁和阿托西班,保胎成功率优于硫酸镁,与β2肾上腺受体激动剂、阿托西班效果相当,孕妇不良事件较阿托西班高,较硫酸镁和β2肾上腺受体激动剂低。
OBJECTIVE To evaluate the curative effect and safety of nifedipine for inhibiting preterm labor. METHODS The relevant data bases were searched. The quality evaluation of studies and the data analysis followed the methods of the Co chrane Collaboration. Meta analysis was performed by RevMan 5.0.23 software. RESULTS Eighteen studies were included. The meta-analysis showed： ①nifedipine was superior to basic treatments in No. of prolonging pregnancy more than 48 h/72 h/ 7 d, neonatal weight and diseases, but inferior in adverse events in pregnant women. ②Compared with magnesium sulfate, nifedipine had shorter effectual time （RR - 0. 48, 95%CI - 0. 88 to - 0. 08）, higher toeolysis rate （RR 1. 12, 95%CI 1.01 to 1.25） and less adverse events in pregnant women （RR 0. 58, 95%CI 0. 46 to II. 73）. ③Compared with β2adrenergic agonists, nifedipine had less adverse events in pregnant women （RR （I. 37, 95%CI 0. 27 to 0. 50）. ④nifedipine had shorter effectual time but higher adverse events rate than atosiban. CONCLUSION Nifedipine was superior to basic treatments in tocolysis rate, neonatal weight and diseases, but inferior in adverse events in pregnant women. Compared with other tocolytics, nifeidpine had shorter effectual time than magnesium sulfate and atosiban, higher tocolysis rate than magnesium sulfate, lower adverse events rate than magnesium sulfate and β2 adrenergic agonists, but higher adverse events rate than atosihan.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2011年第4期300-305,共6页
Chinese Journal of Hospital Pharmacy
